Artemisinin Combination Therapy Market Size, Share, By Therapy Type (Artemether + Lumefantrine, Artesunate + Amodiaquine, Dihydroartemisinin + Piperaquine, Artesunate + Mefloquine, Artesunate + Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate, and Others), End User (Hospitals, Clinics, Government Health Facilities, NGO & International Health Organization Programs, and Others), and Region - Trends, Analysis, and Forecast till 2035

Artemisinin combination therapy market size was valued at USD 684.4 Million in 2025 and is expected to reach USD 1409.2 Million by 2035, growing at a CAGR of 8.3%.

Artemisinin Combination Therapy (ACT) uses an artemisinin-based compound in combination with one or more partner drugs to treat malaria, increasing efficacy and reducing the risk of drug resistance.

Due to the significant prevalence of malaria, particularly in Southeast Asia and sub-Saharan Africa, and the medication's strong capacity to fight off drug-resistant strains of Plasmodium falciparum, the market for artemisinin combination treatments has expanded. The WHO's standards and funding programs, as well as other worldwide health initiatives, have made ACTs more affordable and widely available. Additionally, ongoing pharmaceutical advancements have increased treatment effectiveness and patient compliance, both of which have contributed to the market's expansion.